(Q36899084)

17 August 2017

1 reference

title

Improving vaccines by incorporating immunological coadjuvants (English)

1 reference

17 August 2017

1 reference

Michael P Brown

3

0 references

John D. Hayball

object named as

John D Hayball

series ordinal

4

0 references

author name string

Cara K Fraser

series ordinal

1

1 reference

PubMed ID

17669010

17 August 2017

Kerrilyn R Diener

series ordinal

2

1 reference

17 August 2017

1 August 2007

1 reference

Expert Review of Vaccines

17 August 2017

1 reference

17 August 2017

6

1 reference

17 August 2017

4

1 reference

17 August 2017

559-578

1 reference

The rational design of vaccines

17 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Recent advances in vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Co-stimulatory agonists as immunological adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Methods of ensuring vaccine safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Targeting the innate immune response with improved vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Vaccine manufacturing: challenges and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Vaccine adjuvants: current state and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Cooperation of Toll-like receptor signals in innate immune defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Toll-like receptor signalling and the clinical benefits that lie within

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Pathogen recognition and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Pathogen recognition with Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Nod-like proteins in immunity, inflammation and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Innate recognition of intracellular bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

NLRs join TLRs as innate sensors of pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Innate immune recognition of viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

5'-Triphosphate RNA is the ligand for RIG-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Innate immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Dendritic cells in pathogen recognition and induction of immune responses: a functional genomics approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Steady-state and inflammatory dendritic-cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Viruses and interferon: a fight for supremacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Natural killer cells in antiviral defense: function and regulation by innate cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Division of labor and cooperation between dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Murine plasmacytoid dendritic cells induce effector/memory CD8+ T-cell responses in vivo after viral stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Activation of dendritic cells: translating innate into adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Effector and memory CTL differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Signals required for programming effector and memory development by CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Asymmetric T lymphocyte division in the initiation of adaptive immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Regulation of the T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Translating innate immunity into immunological memory: implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Antigen-independent memory CD8 T cells do not develop during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

CD40/CD154 interactions at the interface of tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Maintenance of B-cell memory by long-lived cells generated from proliferating precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Memory B-cell persistence is independent of persisting immunizing antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Antigen-specific memory B cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Concerted antigen presentation by dendritic cells and B cells is necessary for optimal CD4 T-cell immunity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Control of CD4+ T-cell memory by cytokines and costimulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Aluminium adjuvants--in retrospect and prospect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Mechanisms of stimulation of the immune response by aluminum adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

(How) do aluminium adjuvants work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Natural adjuvants: endogenous activators of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

TLR4 agonists as immunomodulatory agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

God's gift to women: the human papillomavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

NODs: intracellular proteins involved in inflammation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

The toxicology of interleukin-12: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Novel approaches to vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Dendritic cells internalize vaccine adjuvant after intramuscular injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Saponin-adjuvanted particulate vaccines for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

ISCOM-based vaccines: the second decade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Generation and maintenance of mucosal memory B cell responses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Vaccine approaches to prevent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Advances in tuberculosis vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Chitosan and its derivatives in mucosal drug and vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

DNA vaccines: immunology, application, and optimization*

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Rational design of gene-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Plasmid DNA vaccination: mechanism of antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Cytokine, Chemokine, and Costimulatory Molecule Modulation to Enhance Efficacy of HIV Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Recombinant virus-expressed bovine cytokines do not improve efficacy of a bovine herpesvirus 1 marker vaccine strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Virus-like particles: passport to immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Virus-like particles: designing an effective AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Interleukin-21 mRNA expression during virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Immunostimulatory combinations: designing the next generation of vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

The Development and Impact of Tuberculosis Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Migratory Dendritic Cells Transfer Antigen to a Lymph Node-Resident Dendritic Cell Population for Efficient CTL Priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime/protein boost strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN? or IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.559

21 January 2018

Identifiers

DOI

10.1586/14760584.6.4.559

1 reference

17 August 2017

1 reference

PubMed ID

17669010